VRSK — Verisk Analytics, Inc.

Analyst ratings skew Hold (15 holds vs. 9 buys/strong buys and 1 sell), and the average price target of roughly $229 implies about 20% upside, yet the stock is ~30% off its high. The market appears to be weighing steady subscription growth and strong free cash flow against litigation, debt, and a premium-looking multiple, so sentiment is constructive but cautious.

Revenue growth has genuinely decelerated from ~8.6% YoY in Q4 2024 and ~7.8% in Q2 2025 to ~4.4% in Q2 2026; this is a trend, not a one-quarter blip. Sequential revenue growth remains positive, operating margin is stable around 43-46%, and TTM free cash flow came to about $1.24B. Quarterly EPS is noisy due to buybacks, taxes, and one-offs, so revenue and FCF tell the cleaner underlying story.

On trailing numbers VRSK looks cheap relative to its own history: P/E of 29.3x and P/S of 7.9x versus 5-year averages of 43.4x and 12.6x, respectively. But it is not objectively cheap: that is ~24.8x forward EPS (191.02 / 7.712) for roughly 4% revenue growth. The stated PEG of 0.29 is a byproduct of buyback-driven EPS growth and overstates cheapness; fair-to-slightly-rich on absolute terms, cheap only against an elevated historical baseline.

The market is not pricing in a full re-rating to Verisk's historical mid-40s P/E, but it is still pricing in continued EPS growth. At $191, the stock implies ~25x forward EPS; if Verisk delivers ~$7.71 FY EPS through buybacks, margin discipline, and mid-single-digit organic growth, the stock is underpriced. If growth slips further or the AccuLynx case and leverage create lasting overhangs, the current multiple has little downside cushion.

As of 2026-08-27, RSI was 53.3, neutral; price was 2.3% above the 20-day SMA and 1.2% above the 50-day SMA, but 2.2% below the 200-day SMA. That is a sideways/repairing chart after a large pullback, not an overbought breakout and not a confirmed downtrend. A decisive move back above the 200-day would improve timing; losing $185 would likely negate the near-term base.

• Interest rates and debt service: elevated rates pressure the cost of carrying $4.2B of long-term debt and can compress high-multiple software/data names.
• Catastrophe and climate exposure: severe weather events keep demand strong for Verisk's risk models, but also create volatility in client claims-related spending.
• Property & casualty insurance cycle: a still-firm P&C pricing environment supports underwriting data spend, while a sharp softening would pressure growth.
• AI adoption: XactAI and AI-infused underwriting products are both an opportunity and a required reinvestment area that could pressure near-term margins.
• Legal/regulatory overhang: the Delaware AccuLynx ruling is an unresolved litigation risk that can affect sentiment and capital allocation.

• Q3 2026 earnings expected late October 2026, with scrutiny on organic subscription growth, XactAI monetization, and margin trajectory.
• North Atlantic hurricane season and global catastrophe activity, which drive demand for Verisk's loss-modeling and claims analytics.
• Resolution or successful appeal of the AccuLynx litigation, removing a legal overhang.
• Continued buybacks and any Fed rate-cut cycle, which would ease debt-service pressure and support multiple re-rating.

• AccuLynx Delaware ruling: Verisk disagrees and may appeal, but an adverse final outcome could mean material damages.
• Negative stockholders' equity (-$1.19B as of Q2 2026) and $4.2B of long-term debt reduce financial flexibility and make the balance sheet look fragile even if operations are solid.
• Organic revenue growth has slowed to ~4%, and continued deceleration would challenge the premium multiple.
• P/E de-rating risk: if rates stay elevated or growth disappoints, the stock could mean-revert below its current ~25x forward earnings multiple.
• Client spending sensitivity: if P&C insurance margins compress, insurers may cut back on data and analytics subscriptions.

Verisk is a high-quality data and analytics franchise with roughly 84% recurring revenue, ~45% operating margins, and strong free cash flow, but organic growth is only mid-single-digit. At $191 as of 2026-08-27, the stock is well below both its historical multiple and the consensus target, so the risk/reward skews positive for a long-term investor willing to tolerate balance-sheet leverage and litigation noise.

I applied a justified forward P/E of 28.5x to consensus FY2026 EPS of $7.712, giving $219.79. That multiple is a discount to Verisk's 5-year average P/E of 43.4 but a modest premium to its current ~24.8x forward multiple, reflecting the company's quality and recurring revenue while acknowledging slower growth and higher leverage.